Life sciences firms climb after Pfizer drug pricing agreement with US government

Revvity

30/09/2025 20:56

** Shares of life science firms rise after Pfizer PFE.N reaches drug pricing agreement with the U.S. government to cut Medicaid prescription drug prices and introduce new drugs at "most favored nation" pricing, President Donald Trump said

** Leerink Partners says "PFE's announcement of its participation in a direct to consumer program "TrumpRx" appears to be lifting the MFN (Most Favored Nation) pricing overhang across the life science tools space"

** Shares of Danaher DHR.N were up 6.2%, while Repligen RGEN.O up 7.3%

** Thermo Fisher Scientific TMO.N up 5.1%, Waters WAT.N up 3.3% while Revvity RVTY.N up 4.1% and Bio-Techne TECH.O up 5.9%

** Brokerage adds "this news potentially provides an off-ramp to the pressures seen by Life Sciences and Tools companies and potential for upside if the onshoring of manufacturing plants and facilities were to materialize (even though tools purchases maybe 2-3 years away)"

** Including sessions moves, DHR down 14.1%, RGEN down 8.2%, TMO down 6.8%, WAT down 19.5%, while RVTY down 21.6% and TECH down 23.5% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))